The teenager – named in reports as Natalie Morton – died on Monday in hospital shortly after receiving the HPV1 Cervarix jab at the Blue Coat Church of England School in Coventry.
She apparently suffered a “rare but extreme reaction” after being given the injection, with a number of other girls also suffering dizziness and nausea and being sent home.
Health bosses in Coventry have launched an immediate investigation into her death, also quarantining the batch of Cervarix allocated to the school as a “precautionary measure”.
Charmaine Dunn-Myria, 15, who was in the same year as Natalie, said pupils were in tears after being told about the death.
She told the Daily Telegraph: “There was panic around the school when we found out what happened. Girls were in tears in the corridors and everyone was in shock. I had my jab as well and I was really worried about it and that something was going to happen to me.
“They never told us that there was any danger in these jabs. I didn’t know you could get sick or die from them.
Related article by The Daily Mail
Cervarix v Gardasil
- Cervarix was chosen for the NHS programme because it offered ‘best overall value for the NHS’.
- The vaccine, made by GlaxoSmithKline, beat off its rival Gardasil, made by Merck, for the lucrative contract last year.
- The jab is currently being offered to girls aged 12 and 13 years to protect against strains of the human papillomavirus (HPV), which is sexually transmitted and causes most cases of cervical cancer.
- Both vaccines are equally effective against HPV strains, but Gardasil also protects against 90 per cent of genital warts.
- However, the Department of Health secured a deal which meant a catch-up programme could be offered to older girls.
- Around £100 million was earmarked for the programme involving young girls, while the two-year catch-up programme was expected to cost a further £20 million.
- The NHS pays £80 a dose, plus admin and staff costs, and three jabs are given altogether.